Improved p50 auditory gating with ondansetron in medicated schizophrenia patients.
Am J Psychiatry
; 162(2): 386-8, 2005 Feb.
Article
em En
| MEDLINE
| ID: mdl-15677607
ABSTRACT
OBJECTIVE:
Most schizophrenia patients have a deficit in auditory sensory gating, which appears to be mediated by the alpha-7 nicotinic receptor, that is not improved with conventional antipsychotic treatment. This study examined the effects of ondansetron, a highly selective 5-HT3 antagonist, on the P50 auditory evoked potential.METHOD:
Eight medicated outpatients with schizophrenia were given either ondansetron (16 mg) or placebo in a double-blind, placebo-controlled design. Evoked potentials were recorded at baseline and 1 hour, 2 hours, and 3 hours after receipt of drug.RESULTS:
There was a highly significant improvement in P50 gating after ondansetron treatment. The maximal treatment difference was at 2 hours posttreatment (ondansetron mean=41.4%, SD=39.7%; placebo mean=80.2%, SD=21.3%).CONCLUSIONS:
Ondansetron significantly enhanced P50 auditory gating in schizophrenia patients treated with typical antipsychotics.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Esquizofrenia
/
Antagonistas da Serotonina
/
Antipsicóticos
/
Ondansetron
/
Potenciais Evocados Auditivos
Tipo de estudo:
Clinical_trials
/
Diagnostic_studies
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article